FDA APPROVES SIMPONI DRUG TO ULCERATIVE COLITIS

The food and Drug Administration has approved a new drug "Simponi" which is also called a "Golimumab" to treat patients with moderate to severe ulcerative Colitis disease which affects the Colon in the intestine. Golimumab is a human monoclonal anti-body which is used as an Immune suppressive drug and marked by the name Simponi. Ulcerative colitis is a chronic disease  which causes ulcers in the large intestine in the colon. 

*SYMPTOMS

• Abdominal discomfort
• Gastro intestinal bleeding
• Diarrhea
• Pain in stomach 

Andrew E. Mulberg, M.D deputy director of division of Gastro

enterology and inborn errors products in the FDA said that Simponi is the new treatment which is effective for patients who suffers from ulcerative colitis. About 513 patients of moderate to severe ulcerative colitis for diagonised and treated with Simponi shown a effective response and viewing through endoscopy show an improvement in colon after six weeks time. The common side effects shown to the patients who are treated with Simponi are redness in eyes, upper resipratory problems, reactivation of Hepatitis B, Lymphoma, Heart blockage, Nervous system Disorder,  fungal and allergic reaction.

Article of newly drug Simponi